high - Investment banking advisory is highly procyclical. M&A activity correlates strongly with CEO confidence, equity valuations, and credit availability. During expansions (2021-2022), M&A volumes surge as companies pursue growth through acquisitions and private equity deploys record dry powder. Recessions typically see 30-50% declines in M&A volumes as strategic uncertainty rises and financing becomes scarce. However, restructuring advisory provides partial offset during downturns, creating asymmetric but still cyclical exposure. The 27% revenue growth and 71% net income growth reflect the 2024-2025 recovery in deal activity from 2023 lows.

Rising rates have dual effects: (1) Negative for M&A—higher discount rates reduce acquisition valuations and increase financing costs, dampening deal activity, particularly for leveraged buyouts. The 2022-2023 rate surge caused M&A volumes to decline 40%+ from 2021 peaks. (2) Positive for restructuring—higher rates stress overleveraged balance sheets, creating advisory opportunities in debt exchanges, bankruptcy proceedings, and liability management. Net effect is typically negative in early rate-hike cycles, potentially positive if rates stay elevated long enough to trigger distress wave.

value with cyclical timing focus - The stock attracts investors seeking exposure to M&A cycle recovery at depressed valuations. Current 3.1x P/S and 8.8x P/B are below historical peaks (5-6x P/S in strong M&A years), appealing to value investors betting on deal volume normalization. The 8.9% FCF yield and capital return program (dividends plus buybacks) attract income-focused value investors. However, extreme earnings volatility (71% net income growth this period) deters pure dividend investors. Hedge funds and tactical allocators use the stock for cyclical positioning around M&A inflection points.